PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies | Zendy

Jamie Garside | Zendy; Nollaig Healy | Zendy; Hervé Besson | Zendy; Ruben Hermans | Zendy; Finlay MacDougall | Zendy; Damien Lestelle | Zendy; Joris Diels | Zendy; Wafae Iraqi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies

Author(s) -

Jamie Garside,

Nollaig Healy,

Hervé Besson,

Ruben Hermans,

Finlay MacDougall,

Damien Lestelle,

Joris Diels,

Wafae Iraqi

Publication year - 2017

Publication title -

journal of comparative effectiveness research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.567

H-Index - 23

eISSN - 2042-6313

pISSN - 2042-6305

DOI - 10.2217/cer-2017-0046

Subject(s) - ibrutinib , medicine , real world data , randomized controlled trial , clinical trial , oncology , medical physics , data science , leukemia , computer science , chronic lymphocytic leukemia

Aim: PHEDRA (Platform for Haematology in EMEA: Data for Real World Analysis) is a unique, noninterventional project based on secondary data collection from real-world (RW) patient-level (health record) databases to understand treatment patterns in hematological malignancies. It compares ibrutinib's effectiveness with alternative treatments using RW data (RWD) and randomized clinical trials data. Materials & methods: RWD are cleaned, validated, harmonized into a Common Data Model, and analyzed statistically alongside randomized clinical trial data. Treatment outcomes include overall and progression-free survival. Results: To date, RWD (four databases) are available for 2840 patients in three indications, collected between 1990 and 2017. Conclusion: PHEDRA is an innovative approach to generate evidence to inform optimal treatment decisions in RW settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research